A review of Rhino-orbitocerebral mucormycosis IN COVID

Abstract

This is a review article. We have collected data from the pubmed, through the various articles published since the inception of COVID-19 in 2019 to October 2021. Rhino-orbital-mucormycosis (ROCM) is increasingly reported in COVID 19 patients, either during or after the recovery from the disease. It is a fulminating infection involving nasal mucosa, paranasal sinuses, further involving orbit and the brain. The major underlying pathology is the immunocompromised status of the patient and aggressive nature of the fungus. The patients present with spectrum of signs and symptoms depending on the stage of involvement. The diagnosis can be done by various microbiological tests and the treatment depends upon the stage of the disease. The mainstay of treatment involves reversal of the patient's immunocompromised state, aggressive treatment with systemic antifungals and surgical debridement. The prognosis is usually grave if diagnosis is delayed. We are still learning about the ROCM in COVID19, and have summarized the available information about the disease.'